Testosterone is a natural androgen and the active ingredient in prescription anabolic steroid medicines. In medical care, treatment follows a diagnosis and uses a regulated product. Use for physique or performance lies outside approved uses. Forms and esters change delivery and exposure patterns; none creates a safe unprescribed option.
Evidence boundary: findings from prescribed treatment cannot be carried into bodybuilding use, mixed drug exposure or an unregulated product. A vial, tablet or gel label cannot prove its contents unless the supply chain and product record are known.
Medical, legal and sport sources checked 2 September 2026. This page gives general information. It does not provide a diagnosis, prescription, dose, cycle, purchase route, product authentication, drug test timing or advice for avoiding a sport rule.
What does testosterone steroid mean?
Testosterone is a steroid hormone made in the body and a medicine made to pharmaceutical standards. It belongs to the anabolic androgenic steroid class because it activates the androgen receptor. Its effects reach reproductive tissues, muscle, bone, blood cell production, skin and other systems. The word steroid here does not mean a corticosteroid such as prednisone.
The chemical formula for testosterone is C19H28O2. Names such as testosterone cypionate, testosterone enanthate and testosterone undecanoate refer to ester forms. The body removes the ester before the parent hormone acts. A blend such as Sustanon contains more than one testosterone ester. An ester changes delivery. It does not change the active hormone into a separate drug class.
The page what testosterone is and how the body regulates it covers normal hormone production in more detail. This page focuses on testosterone as a prescription steroid medicine and as the claimed ingredient in nonmedical products.
How do natural testosterone, prescribed treatment and nonmedical use differ?
The same hormone name can appear in three very different settings. The purpose, product controls, exposure pattern and evidence are not interchangeable.
| Setting | Purpose | Product and oversight | What the evidence can answer | Boundary |
|---|---|---|---|---|
| Hormone made by the body | Normal endocrine and reproductive function | No medicine or seller is involved | Physiology, normal variation and causes of deficiency | A symptom or one laboratory result does not diagnose a hormone disorder |
| Prescription testosterone | Replacement after a clinician diagnoses an appropriate condition | Named medicine, regulated manufacturing, product label, prescriber and pharmacy | Benefits and harms in studied patients using defined products | Results remain tied to the diagnosis, product, amount, route and study population |
| Nonmedical testosterone use | Physique, strength or performance goals | May involve high exposure, combined drugs or an unregulated product | Class research can identify concerns, but personal benefit and risk cannot be predicted | No controlled trial or normal test result creates a safe nonmedical plan |
A prescription indication cannot be transferred to a physique goal. The cardiovascular findings came from a regulated gel trial. They do not establish the effects of high amounts, ester blends, combined drug use or products with uncertain contents.
How does testosterone act in the body?
Testosterone binds to the androgen receptor. The receptor changes gene activity in responsive tissues. Some testosterone becomes dihydrotestosterone through the enzyme 5 alpha reductase. Some becomes estradiol through aromatase. These pathways help explain effects on sexual function, prostate tissue, skin, bone, muscle and breast tissue.
Testosterone from outside the body sends feedback to the hypothalamus and pituitary. Luteinizing hormone and follicle stimulating hormone can fall. Testosterone inside the testes and sperm production may fall with them. A blood testosterone result during treatment cannot show that fertility has been preserved.
Androgen exposure can raise red blood cell production and affect blood pressure or fluid balance. It may also alter skin oil production, sleep or mood in some people. A plausible pathway shows that an effect can occur. It cannot prove the cause of one person’s symptom or state how often that outcome will occur.
Which testosterone forms and esters are used in medicine?
Products approved by the FDA include topical gel, skin patches, buccal systems and injections. Other current United States labels cover oral, nasal and implanted products. Availability differs by country, and each product has its own indication, warnings, handling rules and follow up needs.
| Form family | Examples | Care questions tied to the form | What the form name cannot prove |
|---|---|---|---|
| Injection | Testosterone cypionate, testosterone enanthate and testosterone undecanoate | Release pattern, local reaction, blood level timing and product specific warnings | A safer nonmedical plan, sterility or the contents of an unregulated vial |
| Skin product | Gel, solution and patch | Skin reaction, transfer to another person and product specific handling | That two topical products use the same strength or create the same exposure |
| Oral product | Testosterone undecanoate capsules | Absorption, food effects, blood pressure warnings and the current label | That it behaves like another oral anabolic steroid or suits every patient |
| Nasal, buccal or implant product | Product dependent formulations | Local effects, release pattern, reversibility and follow up | That a route removes class effects or fertility suppression |
| Ester blend | Sustanon | Which esters are present, country specific approval and product labeling | That a blend is better, safer or approved in every country |
No form is safest for every patient. Diagnosis, fertility plans, health history, likely contact with children or partners, ability to follow the label and access to medical review can change the choice. This page does not reproduce dose or administration instructions.
When is testosterone treatment used in medical care?
United States testosterone products have long carried indications for males with deficiency or absence of endogenous testosterone. The cause may involve the testes, pituitary or hypothalamus. The Endocrine Society advises diagnosis only when compatible symptoms or signs occur with consistently low, accurately measured testosterone concentrations. The cause should be investigated rather than inferred from fatigue, libido, mood or a single result.
Regulatory wording is changing. In February 2025, the FDA removed boxed warning language about increased cardiovascular outcomes and required blood pressure warnings across the product class. In June 2026, the FDA requested removal of the earlier age related limitation and requested new prostate cancer and enlarged prostate wording. Product labels can change on different dates, so the label for the prescribed medicine remains the product record to check.
The June 2026 request did not turn muscle gain, fat loss, ordinary aging or athletic performance into approved treatment goals. The Endocrine Society’s July 2026 statement kept diagnosis at the center of care and did not support population screening of men without symptoms. This United States summary does not describe every clinical use or every jurisdiction.
What does treatment evidence show?
For men with an appropriate diagnosis, testosterone treatment can restore or maintain male sexual characteristics and improve some symptoms of testosterone deficiency. Benefit varies by cause, symptom, product and baseline health. Treatment is not a general answer to tiredness, low mood, weight gain or reduced athletic progress because those concerns have many possible causes.
A large cardiovascular outcomes trial studied more than 5,200 men with hypogonadism who had cardiovascular disease or raised cardiovascular risk. Major cardiovascular events occurred in 7.0 percent of the testosterone gel group and 7.3 percent of the placebo group. The FDA found no new signal for the trial’s main cardiovascular outcome. The gel label reported venous clot events in 1.7 percent of the testosterone group and 1.2 percent of the placebo group. These findings belong to that product, population and trial design.
Required ambulatory blood pressure studies led the FDA to add blood pressure warnings across testosterone products. The absence of an excess in the trial’s main outcome does not mean treatment has no cardiovascular effects. It cannot clear high exposure, combined anabolic steroid use or an unregulated product.
How strong is the evidence for common testosterone claims?
| Claim or question | Best source type | Confidence | Limit |
|---|---|---|---|
| Testosterone is a natural hormone and an anabolic androgenic steroid medicine | Chemical records, physiology and medicine labels | High | This identity does not establish a diagnosis or authenticate a product |
| Hypogonadism needs symptoms or signs plus consistently low measurements | Clinical guideline and 2026 professional statement | High for the diagnostic principle | Test timing, assay quality and the cause still need clinical assessment |
| Treatment can help appropriately diagnosed patients | Controlled trials and clinical guidelines | Moderate to high for selected outcomes | Benefit differs by symptom, cause, product and patient |
| The main cardiovascular outcome did not rise in the large trial | Large randomized trial and FDA review | High for the studied setting | The result does not cover bodybuilding exposure, combined drugs or uncertain products |
| Testosterone can raise blood pressure | Required ambulatory studies and product labeling | High for a class warning | The size and clinical effect differ among people and products |
| External testosterone can suppress sperm production | Endocrine physiology, guideline and labeling | High | Recovery time and completeness cannot be predicted for one person |
| One ester or route is the safest nonmedical choice | No adequate controlled evidence | Unsupported | Route differences do not remove class risk, product uncertainty or the need for diagnosis |
| Current treatment does not raise prostate cancer risk | Trials and epidemiologic research reviewed by the FDA | Reassuring but incomplete | Long latency and limited follow up leave long term uncertainty |
What health risks are linked to testosterone?
Risk changes with the diagnosis, amount, duration, route, age, health history, other drugs and product quality. Prescribed treatment can cause adverse effects even when it is medically appropriate. Nonmedical exposure adds uncertainty from high amounts, combined substances and products that may not match their labels.
| Concern | What may change | Care signal |
|---|---|---|
| Blood pressure and fluid balance | Blood pressure may rise; fluid retention can worsen heart, kidney or liver disease | Severe headache with neurologic change, chest pressure or severe breathlessness needs urgent care |
| Red blood cells | Hemoglobin and hematocrit can rise | A result needs clinical interpretation; symptoms of a clot or stroke need urgent care |
| Venous clot | Clots in a leg vein and clots reaching the lungs have been reported | A painful swollen leg, sudden breathlessness, chest pain or coughing blood needs urgent care |
| Fertility and testicular function | Luteinizing hormone, follicle stimulating hormone and sperm production can fall | Fertility plans should be discussed before treatment; concern after exposure warrants reproductive review |
| Prostate and urination | Prostate symptoms and prostate cancer risk assessment can affect treatment decisions | New urinary retention, blood in urine or fast worsening symptoms needs medical assessment |
| Sleep, mood and dependence | Sleep apnea, irritability, mood change, abuse and dependence can occur | Psychosis, suicidal intent or immediate danger needs emergency help |
| Skin transfer | Gel on skin can expose a child, partner or pregnant person | Unexpected virilizing changes or known contact with wet gel needs prompt product specific advice |
| Injection and product quality | An unregulated product can add contamination, incorrect concentration and infection risk | Fever, spreading redness, drainage or worsening pain needs prompt assessment |
Read testosterone side effects and warning signs for fuller treatment of blood, hormone, fertility, prostate, sleep, mood and skin concerns. The broader anabolic steroid health risk page covers class effects that are not unique to testosterone.
Which situations need closer review before testosterone treatment?
A prescriber reviews the diagnosis and factors that can change the balance of benefit and harm. The 2018 Endocrine Society guideline advised against starting treatment in men planning fertility in the near term. It also listed high hematocrit, untreated severe sleep apnea, uncontrolled heart failure, thrombophilia and defined prostate concerns. A recent heart attack or stroke was another listed condition. A July 2026 society statement kept careful diagnosis, risk assessment and monitoring in place while newer labeling was being requested.
Current gel labeling describes interactions with insulin, oral anticoagulants, corticosteroids and adrenocorticotropic hormone. It warns about fluid retention in people with heart, kidney or liver disease. A medicine list should include prescriptions, nonprescription drugs, supplements and any anabolic steroids used outside medical care.
The June 2026 FDA request would narrow the prostate cancer contraindication and revise the enlarged prostate warning. Long term prostate uncertainty remains. A current product label, the person’s history and the treating clinician should settle the decision rather than an older web summary.
What may a clinician assess?
Assessment starts with symptoms, medical history and repeat accurate testosterone measurements taken at an appropriate time. Luteinizing hormone and follicle stimulating hormone can help distinguish a testicular cause from a pituitary or hypothalamic cause. Other tests depend on the history and may address thyroid disease, medicines, obesity, sleep problems, chronic illness or another source of the symptoms.
Before and during treatment, the clinician may review blood pressure, testosterone concentration, hemoglobin, hematocrit, prostate risk and urinary symptoms. Fertility goals, sleep, mood, swelling and effects tied to the selected product can also shape care. A skin gel needs transfer counseling. An injection or implant raises different local and timing questions.
A laboratory range is not a treatment target for self directed use. One normal result cannot certify continued exposure as safe, show that fertility is intact or rule out a heart, clot, sleep, mood or product problem. Bring the product name, dates, symptoms, medicine list and earlier results to the appointment. The page on talking with a doctor about anabolic steroid use can help organize that information.
What is the legal and sport status of testosterone?
United States federal law places testosterone in Schedule III. Lawful medical supply requires a valid prescription and a regulated dispensing route. State law, import rules and another country’s law may differ. This page does not name sellers or give purchase, shipping or import instructions.
The World Anti Doping Agency’s 2026 list places anabolic agents in category S1 and prohibits them at all times. The 2026 wording clarifies that esters of prohibited anabolic agents are covered. A prescription does not by itself create a therapeutic use exemption. Athletes should check the current list and the rules of their sport body before treatment.
No detection window, masking method, sample manipulation or rule avoidance method appears here. Legal classification, medicine approval and sport status answer separate questions.
Can a label prove that a product contains testosterone?
No. A name, ester, concentration, color, packaging style, batch code or seller claim cannot authenticate an unregulated vial, tablet or gel. A product can contain another androgen, an undeclared mixture, too little or too much active substance, harmful solvent, bacteria, endotoxin or particles.
PubChem and medicine labels describe reference substances and regulated products. They do not verify an item in a reader’s possession. Laboratory analysis answers only the method and sample tested. It does not prove that another vial or batch is the same.
After a suspected exposure or adverse reaction, keep the packaging or clear photographs and record the dates, route, other substances and symptoms. Share that record with a clinician, pharmacist or poison service. Severe symptoms belong with emergency services.
References
- FDA testosterone information. United States Food and Drug Administration. Current indication summary, large cardiovascular trial result and June 2026 label request.
- Requested testosterone label updates issued in June 2026. United States Department of Health and Human Services.
- Testosterone label changes issued in February 2025. United States Food and Drug Administration. Cardiovascular outcome and blood pressure wording.
- Testosterone gel prescribing information. DailyMed. Revised August 2025. Product indication, transfer warning, blood pressure, hematocrit, clot, fertility and interaction information.
- Endocrine Society statement on testosterone treatment. July 2026. Diagnosis, screening and remaining safety questions.
- Endocrine Society clinical practice guideline. 2018. Diagnosis, causes, fertility, conditions needing review and treatment follow up.
- Large cardiovascular safety trial of testosterone treatment. New England Journal of Medicine. 2023.
- United States anabolic steroid fact sheet. Drug Enforcement Administration.
- World Anti Doping Agency 2026 prohibited list. Category S1, anabolic agents.
- PubChem testosterone compound record. National Library of Medicine. Chemical identity and formula.
- Diagnosis and management of anabolic steroid use. Journal of Clinical Endocrinology and Metabolism. 2019.